General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

The meeting culminates the prolonged development of flibanserin, a drug that could be the first approved medical treatment for distressing low sexual desire. Flibanserin offers a favorable safety and efficacy profile for the treatment of Hypoactive Sexual Desire Disorder in women. While we fully endorse the FDA's evidence-based review of the risks and benefits of this treatment, ISSWSH wishes to emphasize the significant unmet need for safe and effective medical therapies to address all women's sexual problems.

Save the Date

ISSWSH Virtual Course 2020
November 6, 13, & 20, 2020  
Virtual
Visit the Course Website

ISSWSH Annual Meeting 2021
March 4-7, 2021   134 days left
Virtual
Visit the Meeting Website

Latest Tweets

We're excited to announce that our 2021 Annual Meeting, scheduled this March in Dallas, is transitioning to a Virtu… https://t.co/RmBUfMGHTb ISSWSH
Not able to join live for the #ISSWSHVirtualCourse? No problem! Registered attendees can watch the recordings on-de… https://t.co/BhBiK7mwrj ISSWSH
Overreaction or appropriate concern? American women consider stockpiling contraceptives https://t.co/Z9Iu2J5RxD ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram